Khaled Musallam: UAE Approves Pyrukynd for Both Alpha and Beta Thalassemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Some welcome and long awaited good news — and a reminder that even in challenging times, progress continues.
I am truly delighted to share that Pyrukynd (mitapivat) has now been approved in the UAE for adult patients with both alpha and beta thalassemia, including transfusion-dependent and non-transfusion-dependent forms.
This approval follows the landmark global ENERGIZE and ENERGIZE-T trials, which we were honored to participate in.
We celebrated when the trials met their primary endpoints. We celebrated when the data were presented in plenary sessions at EHA and ASH.
We celebrated again when the results were published in The Lancet.
But today marks something even more meaningful — the translation of rigorous science into real access for patients in the UAE.
Mitapivat represents the first oral disease-modifying therapy for thalassemia, addressing both anemia and transfusion burden across subtypes.
Bringing such an innovative therapy to our patients is the most important outcome we could have hoped for.
My sincere gratitude to the leadership of Burjeel Holdings for supporting what was our first global clinical trial within the group — a defining step in our research journey.
I am incredibly proud of our research and clinical teams at the Thalassemia and Sickle Cell Center and the Center for Research on Rare Blood Disorders (CR-RBD) at Burjeel Cancer Institute | BCI, BMC | Burjeel Medical City, whose dedication made this milestone possible.
This achievement would not have been possible without the exceptional support of the Department of Health Abu Dhabi.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 17, 2026, 20:19Thomas Muenzel: Proud to Deliver the Sylviane Lévy-Toledano Memorial Plenary Keynote Lecture at ISTH 2026
-
Jul 17, 2026, 20:16Karin Leiderman: Proud of Jamie Madrigal for Receiving the JTH Editors’ Award
-
Jul 17, 2026, 20:14Lily Bull: Presenting New Research and Building Connections at ISTH 2026
-
Jul 17, 2026, 20:12Modern Concepts in Traumatic Disseminated Intravascular Coagulation – JTH
-
Jul 17, 2026, 20:10Nahid A. Qushmaq: Science, Collaboration, and Inspiration at ISTH 2026
-
Jul 17, 2026, 18:20Sarah Jones: Bringing Vessel-on-a-Chip Research to ISTH 2026
-
Jul 17, 2026, 18:06Virginia Barras Sánchez: United by a Commitment to Hemophilia at ISTH 2026
-
Jul 17, 2026, 17:53Micah Grey: Shaping the Future of Hematology at ISTH 2026
-
Jul 17, 2026, 17:32Vasiliki Danilatou: Advancing β-Thalassemia Research at ISTH 2026